Voriconazole serum concentrations in prophylactically treated acute myelogenous leukaemia patients

Mycoses

Volumn 54, Issue 3, 2011, Pages 230-233

  Rüping, Maria J G T ^a   Müller, Carsten ^b   Vehreschild, Jörg J ^a   Böhme, Angelika ^c   Mousset, Sabine ^c   Harnischmacher, Urs ^a   Frommolt, Peter ^b   Wassmer, Gernot ^b   Drzisga, Ivonne ^a   Hallek, Michael ^a   Cornely, Oliver A ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^b UNIVERSITY OF COLOGNE   (Germany)

^c GOETHE UNIVERSITY   (Germany)

Author keywords

Acute myelogenous leukaemia; Antifungal prophylaxis; Therapeutic drug monitoring; Voriconazole

Indexed keywords

KETOCONAZOLE; PLACEBO; VORICONAZOLE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ANTIBIOTIC PROPHYLAXIS; ARTICLE; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EXPOSURE; DRUG MONITORING; FEBRILE NEUTROPENIA; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LUNG INFILTRATE; MALE; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SYSTEMIC MYCOSIS; TREATMENT DURATION;

EID: 79954550935     PISSN: 09337407     EISSN: 14390507     Source Type: Journal    
DOI: 10.1111/j.1439-0507.2009.01803.x     Document Type: Article

References (23)

1. Maschmeyer G, Haas A, Cornely OA. Invasive aspergillosis: epidemiology, diagnosis and management in immunocompromised patients. Drugs 2007; 67: 1567-601.
2. Pfaller MA, Diekema DJ. Epidemiology of invasive candidiasis: a persistent public health problem. Clin Microbiol Rev 2007; 20: 133-63.
3. Kullberg BJ, Sobel JD, Ruhnke M, et al. Voriconazole versus a regimen of amphotericin B followed by fluconazole for candidaemia in non-neutropenic patients: a randomised non-inferiority trial. Lancet 2005; 366: 1435-42.
4. Herbrecht R, Denning DW, Patterson TF, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med 2002; 347: 408-15.
5. Troke P, Aguirrebengoa K, Arteaga C, et al. Treatment of scedosporiosis with voriconazole: clinical experience with 107 patients. Antimicrob Agents Chemother 2008; 52: 1743-50.
6. Stanzani M, Tumietto F, Vianelli N, Baccarani M. Update on the treatment of disseminated fusariosis: focus on voriconazole. Ther Clin Risk Manag 2007; 3: 1165-73.
7. Wingard JR, Carter SL, Walsh TJ, et al. Results of a randomized, double-blind trial of fluconazole (FLU) vs. voriconazole (VORI) for the prevention of invasive fungal infections (IFI) in 600 allogeneic blood and marrow transplant (BMT) patients. In: ASH Annual Meeting. Atlanta, GA, 2007.
8. ClinicalTrials.gov. Voriconazole versus itraconazole in primary prophylaxis of invasive fungal infection (IFI) in subjects with allogeneic hematopoietic stem cell transplants (HSCT) [WWW document]. U.S. National Library of Medicine, 2008. URL [accessed on 12 November 2008]
9. Pascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201-11.
10. Smith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit 2008; 30: 167-72.
11. Howard A, Hoffman J, Sheth A. Clinical application of voriconazole concentrations in the treatment of invasive aspergillosis. Ann Pharmacother 2008; 42: 1859-64.
12. Vehreschild JJ, Bohme A, Buchheidt D, et al. A double-blind trial on prophylactic voriconazole (VRC) or placebo during induction chemotherapy for acute myelogenous leukaemia (AML). J Infect 2007; 55: 445-9.
13. Agilent-Technologies. Informatics & software [WWW document], 2008. URL [accessed on 12 December 2008].
14. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003; 13: 176-81.
15. Walsh TJ, Karlsson MO, Driscoll T, et al. Pharmacokinetics and safety of intravenous voriconazole in children after single- or multiple-dose administration. Antimicrob Agents Chemother 2004; 48: 2166-72.
16. Johnson LB, Kauffman CA. Voriconazole: a new triazole antifungal agent. Clin Infect Dis 2003; 36: 630-7.
17. Hyland R, Jones BC, Smith DA. Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole. Drug Metab Dispos 2003; 31: 540-7.
18. Dodds Ashley ES, Zaas AK, Fang AF, Damle B, Perfect JR. Comparative pharmacokinetics of voriconazole administered orally as either crushed or whole tablets. Antimicrob Agents Chemother 2007; 51: 877-80.
19. Trifilio S, Singhal S, Williams S, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007; 40: 451-6.
20. Purkins L, Wood N, Ghahramani P, Greenhalgh K, Allen MJ, Kleinermans D. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob Agents Chemother 2002; 46: 2546-53.
21. Purkins L, Wood N, Greenhalgh K, Allen MJ, Oliver SD. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br J Clin Pharmacol 2003; 56(Suppl. 1): 10-16.
22. Trifilio S, Pennick G, Pi J, et al. Monitoring plasma voriconazole levels may be necessary to avoid subtherapeutic levels in hematopoietic stem cell transplant recipients. Cancer 2007; 109: 1532-5.
23. Capitano B, Potoski BA, Husain S, et al. Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen. Antimicrob Agents Chemother 2006; 50: 1878-80.